Findings of Research Misconduct, 44774 [2014-18173]
Download as PDF
<![CDATA[
44774
Federal Register / Vol. 79, No. 148 / Friday, August 1, 2014 / Notices
which will in turn decide whether to
proceed with formal advice to GSA
based upon these recommendations.
Dated: July 28, 2014.
Kevin Kampschroer,
Federal Director, Office of Federal HighPerformance Green Buildings, General
Services Administration.
[FR Doc. 2014–18280 Filed 7–31–14; 8:45 am]
BILLING CODE 6820–14–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Jun Fu, Ph.D., University of Texas MD
Anderson Cancer Center: Based on the
Respondent’s admission, the report of
an inquiry conducted by the University
of Texas MD Anderson Cancer Center
(MDACC), and analysis conducted by
ORI in its oversight review, ORI found
that Dr. Jun Fu, former Postdoctoral
Fellow, Department of Neuro-Oncology,
MDACC, engaged in research
misconduct in research supported by
National Cancer Institute (NCI),
National Institutes of Health (NIH),
grants CA56041 and CA127001.
The Respondent has admitted to
knowingly and intentionally falsifying
Figure 8a in the following publication:
• ‘‘Novel HSP90 inhibitor NVP–
HSP990 targets cell-cycle regulators to
ablate Olig2-positive glioma tumorinitiating cells.’’ Cancer Res.
73(10):3062–74, 2013 May 15.
Specifically, the Respondent falsified
survival times of mice to show that
NVP–HSP990 prolonged survival rates
in glioblastoma tumor bearing mice
when experimental data were
incomplete and unusable.
As a result of its inquiry, MDACC has
recommended that the senior author of
this paper take any appropriate steps
with the journal to correct the scientific
literature.
Dr. Fu has entered into a Voluntary
Settlement Agreement (Agreement) and
has voluntarily agreed for a period of
two (2) years, beginning on July 15,
2014:
(1) To have his research supervised;
Respondent agrees that prior to the
submission of an application for U.S.
Public Health Service (PHS) support for
a research project on which the
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
22:09 Jul 31, 2014
Jkt 232001
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research; Respondent
agrees that he shall not participate in
any PHS-supported research until such
a supervision plan is submitted to and
approved by ORI; Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan;
(2) that any institution employing him
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8800.
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Donald Wright,
Acting Director, Office of Research Integrity.
Respiratory Protective Devices—42
CFR part 84—Regulation—(0920–
0109)—Revision—National Institute for
Occupational Safety and Health
(NIOSH), of the Centers for Disease
Control and Prevention (CDC).
[FR Doc. 2014–18173 Filed 7–31–14; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–14–0109]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Proposed Project
Background and Brief Description
This data collection was formerly
named Respiratory Protective Devices
30 CFR part 11 but in 1995, the
respirator standard was moved to 42
CFR Part 84. The regulatory authority
for the National Institute for
Occupational Safety and Health
(NIOSH) certification program for
respiratory protective devices is found
in the Mine Safety and Health
Amendments Act of 1977 (30 U.S.C.
577a, 651 et seq., and 657(g)) and the
Occupational Safety and Health Act of
1970 (30 U.S.C. 3, 5, 7, 811, 842(h),
844). These regulations have, as their
basis, the performance tests and criteria
for approval of respirators used by
millions of American construction
workers, miners, painters, asbestos
removal workers, fabric mill workers,
and fire fighters.
E:\FR\FM\01AUN1.SGM
01AUN1
]]>Agencies
[Federal Register Volume 79, Number 148 (Friday, August 1, 2014)]
[Notices]
[Page 44774]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-18173]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Jun Fu, Ph.D., University of Texas MD Anderson Cancer Center: Based
on the Respondent's admission, the report of an inquiry conducted by
the University of Texas MD Anderson Cancer Center (MDACC), and analysis
conducted by ORI in its oversight review, ORI found that Dr. Jun Fu,
former Postdoctoral Fellow, Department of Neuro-Oncology, MDACC,
engaged in research misconduct in research supported by National Cancer
Institute (NCI), National Institutes of Health (NIH), grants CA56041
and CA127001.
The Respondent has admitted to knowingly and intentionally
falsifying Figure 8a in the following publication:
``Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle
regulators to ablate Olig2-positive glioma tumor-initiating cells.''
Cancer Res. 73(10):3062-74, 2013 May 15.
Specifically, the Respondent falsified survival times of mice to
show that NVP-HSP990 prolonged survival rates in glioblastoma tumor
bearing mice when experimental data were incomplete and unusable.
As a result of its inquiry, MDACC has recommended that the senior
author of this paper take any appropriate steps with the journal to
correct the scientific literature.
Dr. Fu has entered into a Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed for a period of two (2) years,
beginning on July 15, 2014:
(1) To have his research supervised; Respondent agrees that prior
to the submission of an application for U.S. Public Health Service
(PHS) support for a research project on which the Respondent's
participation is proposed and prior to Respondent's participation in
any capacity on PHS-supported research, Respondent shall ensure that a
plan for supervision of Respondent's duties is submitted to ORI for
approval; the supervision plan must be designed to ensure the
scientific integrity of Respondent's research; Respondent agrees that
he shall not participate in any PHS-supported research until such a
supervision plan is submitted to and approved by ORI; Respondent agrees
to maintain responsibility for compliance with the agreed upon
supervision plan;
(2) that any institution employing him shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract; and
(3) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8800.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-18173 Filed 7-31-14; 8:45 am]
BILLING CODE 4150-31-P
